{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:24:50Z","timestamp":1782311090814,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,11]]},"DOI":"10.7759\/cureus.41748","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T06:22:30Z","timestamp":1689142950000},"source":"Crossref","is-referenced-by-count":8,"title":["Myoinositol Versus Metformin in the Treatment of Polycystic Ovarian Syndrome: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Ranita","family":"Bodepudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saniya","family":"Seher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenel A","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivig","family":"Shantha Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resheek","family":"Nerella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basim","family":"Shaman Ameen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jabez","family":"David John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(15)30642-6","article-title":"Amenorrhea associated with bilateral polycystic ovaries","volume":"29","author":"Stein IF","year":"1935","unstructured":"Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935, 29:181-91. 10.1016\/S0002-9378(15)30642-6","journal-title":"Am J Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment","volume":"14","author":"Escobar-Morreale HF","year":"2018","unstructured":"Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018, 14:270-84. 10.1038\/nrendo.2018.24","journal-title":"Nat Rev Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0178","article-title":"Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline","volume":"91","author":"Azziz R","year":"2006","unstructured":"Azziz R, Carmina E, Dewailly D, et al.. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006, 91:4237-45. 10.1210\/jc.2006-0178","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15112589","article-title":"Geographical prevalence of polycystic ovary syndrome as determined by region and race\/ethnicity","volume":"15","author":"Wolf WM","year":"2018","unstructured":"Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race\/ethnicity. Int J Environ Res Public Health. 2018, 15:2589. 10.3390\/ijerph15112589","journal-title":"Int J Environ Res Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.05.009","article-title":"Introduction: Determinants of polycystic ovary\u00a0syndrome","volume":"106","author":"Azziz R","year":"2016","unstructured":"Azziz R. Introduction: Determinants of polycystic ovary\u00a0syndrome. Fertil Steril. 2016, 106:4-5. 10.1016\/j.fertnstert.2016.05.009","journal-title":"Fertil Steril"},{"key":"ref6","article-title":"Polycystic ovarian syndrome: Insights into pathogenesis, diagnosis, prognosis, pharmacological and non-pharmacological treatment","volume":"4","author":"Kabel AM","year":"2016","unstructured":"Kabel AM. Polycystic ovarian syndrome: Insights into pathogenesis, diagnosis, prognosis, pharmacological and non-pharmacological treatment. Pharmaceutical Bioprocessing. 2016, 4:7-12.","journal-title":"Pharmaceutical Bioprocessing"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva D","year":"2016","unstructured":"Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016, 106:6-15. 10.1016\/j.fertnstert.2016.05.003","journal-title":"Fertil Steril"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","author":"The Rotterdam ESHRE\/ASRM\u2010sponsored PCOS consensus workshop group","year":"2004","unstructured":"The Rotterdam ESHRE\/ASRM\u2010sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004, 19:41-7. 10.1093\/humrep\/deh098","journal-title":"Hum Reprod"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2016.00124","article-title":"Poly cystic ovarian syndrome: An updated overview","volume":"7","author":"El Hayek S","year":"2016","unstructured":"El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly cystic ovarian syndrome: An updated overview. Front Physiol. 2016, 7:124. 10.3389\/fphys.2016.00124","journal-title":"Front Physiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2010.217","article-title":"Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis","volume":"7","author":"Goodarzi MO","year":"2011","unstructured":"Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011, 7:219-31. 10.1038\/nrendo.2010.217","journal-title":"Nat Rev Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-1-200207020-00009","article-title":"Metformin: An update","volume":"137","author":"Kirpichnikov D","year":"2002","unstructured":"Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ann Intern Med. 2002, 137:25-33. 10.7326\/0003-4819-137-1-200207020-00009","journal-title":"Ann Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/2042018812437355","article-title":"The effects of old, new and emerging medicines on metabolic aberrations in PCOS","volume":"3","author":"Bargiota A","year":"2012","unstructured":"Bargiota A, Diamanti-Kandarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab. 2012, 3:27-47. 10.1177\/2042018812437355","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0030","article-title":"Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: A comprehensive review","volume":"30","author":"Palomba S","year":"2009","unstructured":"Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: A comprehensive review. Endocr Rev. 2009, 30:1-50. 10.1210\/er.2008-0030","journal-title":"Endocr Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/des262","article-title":"Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study","volume":"27","author":"Fulghesu AM","year":"2012","unstructured":"Fulghesu AM, Romualdi D, Di Florio C, et al.. Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. Hum Reprod. 2012, 27:3057-66. 10.1093\/humrep\/des262","journal-title":"Hum Reprod"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2013.05.011","article-title":"Potential role and therapeutic interests of myo-inositol in metabolic diseases","volume":"95","author":"Croze ML","year":"2013","unstructured":"Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013, 95:1811-27. 10.1016\/j.biochi.2013.05.011","journal-title":"Biochimie"},{"key":"ref16","article-title":"Inositol safety: Clinical evidences","volume":"15","author":"Carlomagno G","year":"2011","unstructured":"Carlomagno G, Unfer V. Inositol safety: Clinical evidences. Eur Rev Med Pharmacol Sci. 2011, 15:931-936.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0243","article-title":"Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials","volume":"6","author":"Unfer V","year":"2017","unstructured":"Unfer V, Facchinetti F, Orr\u00f9 B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocr Connect. 2017, 6:647-58. 10.1530\/EC-17-0243","journal-title":"Endocr Connect"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1849162","article-title":"Effects of Inositol(s) in women with PCOS: A systematic review of randomized controlled trials","volume":"2016","author":"Unfer V","year":"2016","unstructured":"Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. Effects of Inositol(s) in women with PCOS: A systematic review of randomized controlled trials. Int J Endocrinol. 2016, 2016:1-12. 10.1155\/2016\/1849162","journal-title":"Int J Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","author":"The Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group**e1","year":"2004","unstructured":"The Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group**e1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004, 81:19-25. 10.1016\/j.fertnstert.2003.10.004","journal-title":"Fertil Steril"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report","volume":"91","author":"Azziz R","year":"2009","unstructured":"Azziz R, Carmina E, Dewailly D, et al.. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril. 2009, 91:456-88. 10.1016\/j.fertnstert.2008.06.035","journal-title":"Fertil Steril"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref24","article-title":"Chapter 3: Systematic reviews of effectiveness","author":"Tufanaru C","year":"2020","unstructured":"Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Chapter 3: Systematic reviews of effectiveness. JBI Manual for Evidence Synthesis. Aromataris E, Munn Z (ed): JBI, 2020."},{"key":"ref25","article-title":"Myoinositol versus metformin in treating polycystic ovary syndrome in terms of improvement in clinical, hormonal and metabolic parameters: Which one and when?","volume":"11","author":"Agarwal N","year":"2021","unstructured":"Agarwal N, Kulshrestha V, Kumar D, Kachhawa G, Kumar A, Kriplani A, Bhatla N. Myoinositol versus metformin in treating polycystic ovary syndrome in terms of improvement in clinical, hormonal and metabolic parameters: Which one and when?. Indian Obstetrics & Gynaecology (IOG) Journal. 2021, 11:40-9.","journal-title":"Indian Obstetrics & Gynaecology (IOG) Journal"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.5455\/2320-1770.ijrcog20150234","article-title":"A comparative study of metabolic and hormonal effects of myoinositol vs. metformin in women with polycystic ovary syndrome: A randomised controlled trial","volume":"4","author":"Angik R","year":"2015","unstructured":"Angik R, Jajoo SS, Hariharan C, Chimote A. A comparative study of metabolic and hormonal effects of myoinositol vs. metformin in women with polycystic ovary syndrome: A randomised controlled trial. Int J Reprod Contracept Obstet Gynecol. 2015, 4:189-194. 10.5455\/2320-1770.ijrcog20150234","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref27","article-title":"A comparative study of myo-inositol versus metformin in women with polycystic ovary syndrome","volume":"27","author":"Anu M","year":"2021","unstructured":"Anu M, Saraswathi K, David PEJ. A comparative study of myo-inositol versus metformin in women with polycystic ovary syndrome. Annals of RSCB. 2021, 27:3770-83.","journal-title":"Annals of RSCB"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15510","article-title":"Comparison of clinical, metabolic and hormonal effects of metformin versus combined therapy of metformin with myoinositol plus d-chiro-inositol in women with polycystic ovary syndrome (PCOS): A randomized controlled trial","volume":"13","author":"Bahadur A","year":"2021","unstructured":"Bahadur A, Arora H, Ravi AK, et al.. Comparison of clinical, metabolic and hormonal effects of metformin versus combined therapy of metformin with myoinositol plus d-chiro-inositol in women with polycystic ovary syndrome (PCOS): A randomized controlled trial. Cureus. 2021, 13:e15510. 10.7759\/cureus.15510","journal-title":"Cureus"},{"key":"ref29","article-title":"Comparative study on efficacy and safety of myoinositol versus metformin in women with PCOS","volume":"8","author":"Chinthana G","year":"2019","unstructured":"Chinthana G. Comparative study on efficacy and safety of myoinositol versus metformin in women with PCOS. World J Pharm Res. 2019, 8:918-44.","journal-title":"World J Pharm Res"},{"key":"ref30","article-title":"Is myo-inositol better than metformin for treatment of PCOS overweight patients?","volume":"11","author":"Majeed R","year":"2021","unstructured":"Majeed R, Mobashar S, Sher Z, Jan S, Mumtaz H. Is myo-inositol better than metformin for treatment of PCOS overweight patients? . J Soc Obstet Gynaecol Pak. 2021, 11:195-9.","journal-title":"J Soc Obstet Gynaecol Pak"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20200176","article-title":"A prospective study of metformin versus myoinositol plus d-chiroinositol combination therapy in polycystic ovarian syndrome","volume":"9","author":"Jaura S","year":"2020","unstructured":"Jaura S, Kaur I, Singh J, Madan. A prospective study of metformin versus myoinositol plus d-chiroinositol combination therapy in polycystic ovarian syndrome. Int J Basic Clin Pharmacol. 2020, 9:276-81. 10.18203\/2319-2003.ijbcp20200176","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref32","article-title":"Comparison of myoinositol and metformin in women with polycystic ovarian syndrome","volume":"29","author":"Nabi S","year":"2018","unstructured":"Nabi S, Guleria R. Comparison of myoinositol and metformin in women with polycystic ovarian syndrome. Indian Journal of Clinical Practice. 2018, 29:458-63.","journal-title":"Indian Journal of Clinical Practice"},{"key":"ref33","article-title":"A comparative study of efficacy and safety of myoinositol versus metformin in polycystic ovarian syndrome in women","volume":"5","author":"Nehra J","year":"2016","unstructured":"Nehra J, Kaushal J, Singhal SR, Gehlaut VS. A comparative study of efficacy and safety of myoinositol versus metformin in polycystic ovarian syndrome in women. World Journal of Pharmacy and Pharmaceutical Sciences. 2016, 5:884-896.","journal-title":"World Journal of Pharmacy and Pharmaceutical Sciences"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.22159\/ijpps.2017v9i4.16359","article-title":"Comparison of myo-Inositosl versus metformin on anthropometric parameters in polycystic ovarian syndrome in women","volume":"9","author":"Nehra J","year":"2017","unstructured":"Nehra J, Kaushal J, Singhal SR, Ghalaut VS. Comparison of myo-Inositosl versus metformin on anthropometric parameters in polycystic ovarian syndrome in women. Int J Pharm Pharm Sci. 2017, 9:144. 10.22159\/ijpps.2017v9i4.16359","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.13040\/IJPSR.0975-8232.8(4).1664-70","article-title":"A comparative study of myo-inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women","volume":"8","author":"Nehra J","year":"2017","unstructured":"Nehra J, Kaushal J, Singhal SR, Ghalaut VS. A comparative study of myo-inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women. Int J Pharm Sci Res. 2017, 8:1664-70. 10.13040\/IJPSR.0975-8232.8(4).1664-70","journal-title":"Int J Pharm Sci Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.33545\/gynae.2020.v4.i6b.737","article-title":"Comparative study on the use of myoinositol and metformin in the improvement of clinical symptoms and biochemical parameters in women with the polycystic ovarian syndrome","volume":"4","author":"Sangeereni M","year":"2020","unstructured":"Sangeereni M, Duraisingam A. Comparative study on the use of myoinositol and metformin in the improvement of clinical symptoms and biochemical parameters in women with the polycystic ovarian syndrome. Int J Clin Obstet Gynaecol. 2020, 4:87-92. 10.33545\/gynae.2020.v4.i6b.737","journal-title":"Int J Clin Obstet Gynaecol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.18203\/2320-1770.ijrcog20211508","article-title":"Comparative study on efficacy of myo-inositol over metformin in polycystic ovary syndrome patients","volume":"10","author":"Shivani D","year":"2021","unstructured":"Shivani D, Sravanthi P, G NJ. Comparative study on efficacy of myo-inositol over metformin in polycystic ovary syndrome patients. Int J Reprod Contracept Obstet Gynecol. 2021, 10:1899. 10.18203\/2320-1770.ijrcog20211508","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.18203\/2320-1770.ijrcog20202345","article-title":"Randomised controlled trial: Comparing effects of metformin versus myoinositol versus metformin and myoinositol on ovarian functions and metabolic factors in polycystic ovarian syndrome","volume":"9","author":"Thakur SS","year":"2020","unstructured":"Thakur SS, Anjum S, Siddiqui SS. Randomised controlled trial: Comparing effects of metformin versus myoinositol versus metformin and myoinositol on ovarian functions and metabolic factors in polycystic ovarian syndrome. Int J Reprod Contracept Obstet Gynecol. 2020, 9:2542. 10.18203\/2320-1770.ijrcog20202345","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.18370\/2309-4117.2020.56.96-99","article-title":"A comparative study of combination of myo-inositol and D-chiro-inositol versus metformin in the management of polycystic ovary syndrome in obese women with infertility","volume":"56","author":"Thalamati S","year":"2020","unstructured":"Thalamati S. A comparative study of combination of myo-inositol and D-chiro-inositol versus metformin in the management of polycystic ovary syndrome in obese women with infertility. Reproductive Endocrinology. 2020, 56:96-9. 10.18370\/2309-4117.2020.56.96-99","journal-title":"Reproductive Endocrinology"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2018.1540578","article-title":"Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): A meta-analysis of randomized clinical trials","volume":"35","author":"Facchinetti F","year":"2019","unstructured":"Facchinetti F, Orr\u00f9 B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): A meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019, 35:198-206. 10.1080\/09513590.2018.1540578","journal-title":"Gynecol Endocrinol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202104_25565","article-title":"The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: A systematic review and meta-analysis","volume":"25","author":"Azizi Kutenaei M","year":"2021","unstructured":"Azizi Kutenaei M, Hosseini Teshnizi S, Ghaemmaghami P, Eini F, Roozbeh N. The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021, 25:3105-15. 10.26355\/eurrev_202104_25565","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202203_28322","article-title":"Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: A systematic review and updated meta-analysis of randomized controlled trials","volume":"26","author":"Zhang JQ","year":"2022","unstructured":"Zhang JQ, Xing C, He B. Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: A systematic review and updated meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2022, 26:1792-802. 10.26355\/eurrev_202203_28322","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.7439\/ijbr.v6i9.2519","article-title":"Effect of metformin & myoinositol & lifestyle modification in patients of polycystic ovarian disease (PCOD)","volume":"6","author":"Awalekar JC","year":"2015","unstructured":"Awalekar JC, Awalekar C, Jadhav VM, Chivate CG, Patwardhan MH. Effect of metformin & myoinositol & lifestyle modification in patients of polycystic ovarian disease (PCOD). Int J Biomed Res. 2015, 6:698.","journal-title":"Int J Biomed Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/145128-myoinositol-versus-metformin-in-the-treatment-of-polycystic-ovarian-syndrome-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:47Z","timestamp":1707509027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/145128-myoinositol-versus-metformin-in-the-treatment-of-polycystic-ovarian-syndrome-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.41748","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}